Understanding how DACH1 affects kidney disease treatment with glucocorticoids
DACH1 transcriptomic regulation of glucocorticoid-responsive glomerular disease
This study is looking at how a gene called DACH1 affects kidney diseases that are treated with steroids, like minimal change disease and focal segmental glomerulosclerosis, to find ways to make these treatments work better and cause fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10769752 on NIH RePORTER |
What this research studies
This research investigates the role of the DACH1 gene in kidney diseases, particularly those treated with glucocorticoids, such as minimal change disease and focal segmental glomerulosclerosis. The study aims to identify how glucocorticoids affect podocytes, the cells crucial for kidney function, and how DACH1 expression influences their response to treatment. By using mouse models, researchers will explore the potential to enhance the effectiveness of glucocorticoids while reducing their harmful side effects. This could lead to new therapeutic strategies for patients suffering from kidney disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with minimal change disease or focal segmental glomerulosclerosis who are undergoing glucocorticoid treatment.
Not a fit: Patients with kidney diseases not responsive to glucocorticoids or those with other unrelated kidney disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients with proteinuric kidney diseases.
How similar studies have performed: Previous research has shown promise in targeting specific genes to improve treatment outcomes in kidney diseases, suggesting that this approach may yield beneficial results.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Kaufman, Lewis — Icahn School of Medicine at Mount Sinai
- Study coordinator: Kaufman, Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.